Related Experiment Videos
[The cost of chemotherapy]
Christine Lévy1, Julia Bonastre
1Service d'information médicale, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif, France. levy@igr.fr
Bulletin Du Cancer
|January 7, 2004
Summary
Cancer care costs are rising in France, driven by increased incidence, an aging population, and new treatments. Chemotherapy significantly contributes to these escalating health expenditures.
Area of Science:
- Oncology
- Health Economics
- Public Health Policy
Context:
- Rising healthcare expenditures in France over several years.
- Cancer care represents a substantial and increasing portion of the national health budget.
- Previous studies indicated 15-25% of public hospital stays are cancer-related.
Purpose:
- To analyze the financial burden of cancer care in France.
- To identify key factors contributing to the rising costs of cancer treatment.
- To examine the impact of the French reimbursement system on cancer patient management.
Summary:
- Cancer care expenditures in France are significant, estimated at 6 billion euros in public health system budgets, with chemotherapy accounting for 16-18%.
- Pharmaceutical sales for anticancer drugs reached 1.5 billion euros in 2002, largely driven by hospital sector use.
- Factors contributing to the burden include increased cancer incidence, an aging population, and expanded eligibility for chemotherapy.
Impact:
- Highlights the substantial economic impact of cancer on the French healthcare system.
- Underscores the role of new drug pricing, patient demographics, and treatment accessibility in cost escalation.
- Suggests that the current reimbursement system influences patient care pathways and sector-specific resource allocation.